SF3B4

Across TCGA pan-cancer cohorts, SF3B4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SF3B4 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SF3B4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SF3B4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SF3B4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.785	0.214	.006	7	view →
CCRCC	DFS	Median	All	0.718	0.883	.011	7	view →
LUAD	OS	Tertile	II,III,IV	0.809	0.453	.018	4	view →
LSCC	OS	Quartile	II,III,IV	0.941	0.653	.028	3	view →
HNSC	DFS	Tertile	III,IV	0.671	0.874	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SF3B4–PDAC (DFS)

Open the PDAC breakdown →